Open AccessSafety of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: An Update
Author(s) -
Nasser Mikhail,
Soma Wali
Publication year - 2021
Publication title -
journal of infectious diseases and case reports
Language(s) - English
Resource type - Journals
ISSN - 2634-8861
DOI - 10.47363/jidscr/2020(2)132
Subject(s) - dipeptidyl peptidase 4 , covid-19 , type 2 diabetes , dipeptidyl peptidase , medicine , diabetes mellitus , coronavirus , pharmacology , vildagliptin , disease , virology , chemistry , enzyme , endocrinology , biochemistry , infectious disease (medical specialty) , outbreak
Background: Safety of use of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19) is unclear. Objective: To review the most recent data regarding safety of use of DPP-4 inhibitors before and during hospitalization of patients with type 2 diabetes and COVID-19